ImmunoMet is a clinical-stage biotechnological company that specializes in tumor metabolism and immuno-metabolism. It develops a series of small molecules in its biguanide engine targeting metabolic pathways of a tumor and immuno-suppressive cells to control tumor growth and relapse. Immunomet's product candidates are designed to combat tumors by targeting resistant subpopulations of cells.